13-Jun-2026 13:31:50
DRREDDYPress Release
DR. REDDY'S LABORATORIES : LAUNCHES BOSUTINIB TABLETS 400MG IN US
• Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. • The company has collaborated with MSN Laboratories for the product, holding exclusive marketing rights in the US. • Bosutinib Tablets (400mg) was a first-to-file product and is eligible for 180-days of generic drug exclusivity in the US. • The Bosulif® brand had US sales of approximately $253.8 million for the 12-month period ended April 2026.
Dr. Reddy's Laboratories Limited
Open attachment